No abstract

In this paper, we illustrate the potential of ultra-high performance liquid chromatography (UHPLC) coupled with hybrid quadrupole time-of-flight mass spectrometry (QTOF MS) for large scale screening of organic contaminants in different types of samples. Thanks to the full-spectrum acquisition at satisfactory sensitivity, it is feasible to apply both (post)-target and non-target approaches for the rapid qualitative screening of organic pollutants in food, biological and environmental samples. Different strategies have been applied and compared in this work. The first approach consists of target screening based on automatically extracting the exact analyte masses with a narrow mass window (AE10 mDa). The selection of analytes can be made after MS acquisition as non-specific analyte information is required when injecting the samples. The second, non-targeted approach, consists of a first component detection step followed by the search of the detected components in home-made spectral libraries. In this work, two types of libraries have been evaluated: a theoretical database, including the molecular formula of a large number of pollutants ($1000), and an empirical mass spectra library which includes a lower number of compounds for which reference standards were available. In all cases the confidence of the identification process was excellent, thanks to the value of information given in QTOF MS E acquisition mode (i.e. simultaneous acquisition of low and high energy TOF MS spectra in a unique run). Both, target and non-target approaches, are complementary and both have advantages and drawbacks. Their application to different types of samples has allowed the detection of diverse organic compounds, for example the mycotoxin fumonisin B1 in food samples, cocaine and several metabolites in human urine, as well as several pesticides, antibiotics and drugs of abuse in urban wastewater.

No abstract

Background: Uncontrolled proteolysis contributes to cell injury and organ dysfunction in animal models of circulatory shock. We investigated in humans the relationship between septic shock, proteolysis, and outcome. Methods: Intensive care patients with septic shock (n¼29) or sepsis (n¼6) and non-hospitalised subjects (n¼9) were recruited as part of the prospective observational trial 'ShockOmics' (ClinicalTrials.gov Identifier NCT02141607). A mass spectrometry-based approach was used to analyse the plasma peptidomes and the origin of circulating peptides from proteolysis in the enrolled subjects. Results: Evidence of systemic proteolysis was indicated by a larger number of circulating peptides in septic shock patients, compared with septic patients and non-hospitalised healthy subjects. The peptide count and abundance in the septic shock patients were greater in patients who died (n¼6) than in survivors (n¼23), suggesting an association between magnitude of proteolysis and outcome. In silico analysis of the peptide sequences and of the sites of cleavage on the proteins of origin indicated a predominant role for serine proteases, such as chymotrypsin, and matrix metalloproteases in causing the observed proteolytic degradation. Conclusions: Systemic proteolysis is a novel fundamental pathological mechanism in septic shock. Plasma peptidomics is proposed as a new tool to monitor clinical trajectory in septic shock patients. Clinical trial registration: NCT02141607.

No abstract